Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

Inclusion Criteria:

Histologically-proven diagnosis of advanced (AJCC, 7th Edition: stage III or IV) or aggressive solid organ cancer.
Patients must provide written consent for a core needle biopsy sample of tumor tissue (primary or metastatic).
Have evidence of measurable disease (according to RECIST Version 1.1: http:// www.recist.com).
Have an ECOG Performance Score of 0 to 2.
Have a life expectancy of at least 3 months.
Have adequate organ and marrow function
Negative serum pregnancy test for females of childbearing potential.
Have negative test result for HIV and Hepatitis B or C testing.
Have baseline anti-vaccinia antibody titer < 10.

Exclusion Criteria:

Current or anticipated use of other investigational agents or marketed anticancer agent while on study (from the time of enrollment through the time of surgery).
Patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study.
Small pox vaccination for 4 weeks before study therapy and during study treatment.
Have received prior gene therapy or therapy with cytolytic virus of any type.
Have clinically significant cardiac disease
Oxygen saturation <90% measured by pulse oximetry at rest.
Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246) during the course of study.
Have known allergy to ovalbumin or other egg products.
Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers)
Have a history of allergy to iodinated contrast media.
Patients with known brain metastases
Pregnant or nursing